Business & Finance
Tue, April 18, 2017Tue, March 21, 2017Fri, February 17, 2017Mon, January 30, 2017Thu, October 6, 2016Wed, October 5, 2016Tue, October 4, 2016Wed, September 28, 2016Mon, September 26, 2016Fri, September 23, 2016Thu, September 22, 2016Wed, September 21, 2016Tue, September 20, 2016Mon, September 19, 2016Fri, September 16, 2016Thu, September 15, 2016Wed, September 14, 2016Tue, September 13, 2016Mon, September 12, 2016Fri, September 9, 2016Thu, May 9, 2013Wed, May 8, 2013Tue, May 7, 2013Mon, May 6, 2013Sun, May 5, 2013Sat, May 4, 2013Fri, May 3, 2013Thu, May 2, 2013Wed, May 1, 2013Tue, April 30, 2013Mon, April 29, 2013Bio-Matrix Scientific Group's Regen BioPharma Acquires Cancer Vaccine Technology With Initial Focus on Breast Cancer
//business-finance.news-articles.net/content/201 .. hnology-with-initial-focus-on-breast-cancer.html
Published in Business and Finance on Monday, May 6th 2013 at 5:45 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
May 06, 2013 08:30 ET
Bio-Matrix Scientific Group's Regen BioPharma Acquires Cancer Vaccine Technology With Initial Focus on Breast Cancer
Broad-Based Patent Assigned to Regen Covers Gene Silencing Non-Toxic Cancer Immunotherapy
SAN DIEGO, CA--(Marketwired - May 6, 2013) - Regen BioPharma, wholly owned subsidiary of Bio-Matrix Scientific Group, Inc. (
"The blockbuster potential of cancer immune therapies is illustrated by the $1.66 Billion sales of Herceptin2, a monoclonal antibody used to treat breast cancer, in 2011," said David Koos, Chairman and CEO of Bio-Matrix Scientific Group Inc. and its subsidiary, Regen BioPharma Inc. "This newly acquired technology has passed the preclinical stages of testing and we are eager to continue development through the FDA IND process."
The acquired technology covers the use of RNA Interference to specifically inhibit the enzyme indolamine 2,3 deoxygenase (IDO). Tumors are known to escape the immune system by specifically activating this enzyme. In the patent and previous publication, Dr. Min and his team demonstrated that by blocking function of IDO, tumors would enter remission.
"My laboratory is looking forward to working with Bio-Matrix Scientific's Regen BioPharma towards advancing our new method of treating cancer from mice to people," stated Dr. Wei-Ping Min, Professor at the University of Western Ontario. "Having previously published3 with Dr. Koos on our RNA interference technique, I am eager to now expand our collaboration into the area of oncology."
The cancer vaccine market is expected to grow from a 2010 value of US$12.8 billion, to US$17.4 billion by 2018. Approximately 1.5 million Americans are being diagnosed with cancer annually, and the annual overall cost of the disease is estimated to be $230 billion4.
About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:
Bio-Matrix Scientific Group, Inc. (
Disclaimer:
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
1[ http://www.jimmunol.org/content/177/8/5639.full.pdf+html ]
2[ http://www.fiercepharma.com/special-reports/top-10-best-selling-cancer-drugs/herceptin-166-billion ]
3[ http://www.ncbi.nlm.nih.gov/pubmed?term=22289162 ]
